AlphAIAlphAI — Financial news for AI agents
aol.com$ACH

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.

Original reporting
aol.com
Published Aug 19, 2026, 7:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Accendra Health (ACH) Q2 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$ACHBearishHigh
01

Why it matters

The revised guidance suggests lower near-term earnings, but strategic initiatives may mitigate long-term risk.

02

Market read

Earnings miss and guidance downgrade are likely to move ACH stock, with sector peers watching collection trends.

03

What to watch

Potential upside from the new sole-source agreement launching in 2027 and the Sleep Center rollout.

Relevance 8/10Novelty 8/10Timing: pre-market

Background

Accendra Health reported Q2 results below internal expectations, revising full-year guidance amid collection headwinds.

Company-level read

Ticker impact

$ACHBearishHigh confidence
Context

Q2 2026 earnings release with revised full-year revenue and EBITDA guidance, plus debt reduction details.

Expected impact

Potential short-term decline, with volatility as investors reassess valuation.

Evidence & confidence

Revenue guidance lowered and collection issues highlighted; market may react negatively to weaker outlook.

Market effects

Sector

Home-based healthcare and medical device sectors may see broader scrutiny on payer collection trends.

Regional

U.S. healthcare stocks could face pressure amid earnings downgrades.

Global

Limited to U.S. markets; no immediate global macro impact.

Counterpoint

What could challenge this read

Cost reductions and debt paydown could support a rebound if collection issues improve.

Key entities

  • Executive
    Edward Pesicka

    CEO announcing retirement and leading transformation.

  • Executive
    Jonathan Leon

    CFO discussing debt reduction and cash interest.

Read at source← All news

Related articles

$ACHMed

Accendra (ACH) Q3 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q3 2026 revenue of $602M, down 1% YoY, excluding impacts from a large commercial payer loss and asset sale. Adjusted EBITDA was $47.8M. CEO Kenny Gardner-Smith outlined a value creation plan to address performance issues, focusing on reversing revenue declines and improving collections. CFO Jonathan Leon highlighted liquidity strength and debt reduction.

finance.yahoo.com
$ACHMed

Accendra Health Inc (ACH) (Q3 2026) Earnings Call Highlights: Revenue Slips 1% as Guidance

Accendra Health Inc (ACH) reported a 1% revenue decline in Q3 2026, its first annual drop, with adjusted EBITDA at $47.8M. Full-year adjusted EBITDA may be 30% below prior guidance. The company lost market share in sleep and respiratory, and faces operational challenges. Management expects to resolve commercial payer audit issues by Q4 2026 and outlined a turnaround plan for 2027. Net debt is $1.73B, with strong liquidity.

finance.yahoo.com
$ACHMedAI 8/10

Accendra Health Reports Third Quarter 2026 Financial Results

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Accendra Health Reports Third Quarter 2026 Financial Results ​ RICHMOND, VA – November 5, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herei

SEC EDGAR 8-K
$ACHMedAI 8/10

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.

fool.com
$ACHMedAI 8/10

Accendra Health Reports Lower Q2 Revenue, Sets 2026 Guidance; Adopts Tax Asset Plan; Stock Down

Accendra Health (ACH) reported Q2 2026 revenue of $613.2 million, down from $681.9 million a year earlier, with GAAP net loss of $89.1 million ($1.16/share). Non-GAAP adjusted net loss was $14.3 million. Adjusted EBITDA fell to $60.1 million and free cash flow was -$25.1 million. The company guided FY2026 revenue $2.45-$2.55 billion and adjusted EBITDA $300-$320 million, and adopted a tax asset preservation plan.

rttnews.com